CDX0159-17
20 evidence topics · 3 sources
Objective
Purpose stated in the ClinicalTrials.gov brief summary
Time to disease worsening as the aim in the detailed description
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Enrolling by invitation” (opens the source at this quote in a new tab)
“Study Start (Actual) 2025-11-25” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2028-09” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2028-09” (opens the source at this quote in a new tab)
“First Posted 2025-12-01” (opens the source at this quote in a new tab)
“Last Update Posted 2026-11-02” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Long-term extension established and ongoing at the phase 3 topline
Study design
Observation and retreatment groups assigned by UAS7 at entry, and duration of participation
Observation and retreatment groups described in the Form 10-Q
Eligibility criteria
Key inclusion criteria in the ClinicalTrials.gov record
Key exclusion criteria in the ClinicalTrials.gov record
Treatment
Groups and interventions in the ClinicalTrials.gov record
| Group | Description in the record |
|---|---|
| Group 1, observation | “Standard of care treatment (at least 2nd generation Type 1 antihistamines [H1AH] with or without other permitted background medications) for 52 weeks.” |
| Group 1, rescue for worsening disease | “For participants with worsening disease (UAS7 score of 16 or greater at any time between Weeks 0-24), barzolvolimab will be administered once as a 300 mg subcutaneous injection followed by 150 mg every 4 weeks for up to 52 weeks.” |
| Group 2, retreatment | “Barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks” |
| Barzolvolimab intervention | “Subcutaneous Administration” |
| Standard of care intervention | “Observational/Standard of Care” |
Treatment of observation group participants whose disease flares in the first 6 months
Study outcomes
Rationale for using time to disease worsening as the primary endpoint
Primary outcome measures in the ClinicalTrials.gov record
Definition of the UAS7 in the ClinicalTrials.gov record
Secondary outcome measures for the observation group (Group 1)
Secondary outcome measures for the retreatment group (Group 2)
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the ClinicalTrials.gov record
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: limitations of the available long-term extension evidence
- The phase 3b long-term extension (NCT07256392) started 2025-11-25, is enrolling by invitation, and has an estimated primary completion of 2028-09. No disposition, baseline, efficacy, quality of life, or safety results have been reported.
- The design is non-randomized and open label. Participants are assigned by UAS7 at entry: those with UAS7 below 16 enter an observation group on standard of care (at least second-generation H1 antihistamines), and those with UAS7 of 16 or greater enter a barzolvolimab retreatment group.
- Retreatment and rescue of observation-group participants with worsening disease both use a 300 mg loading dose followed by 150 mg every 4 weeks; the 300 mg every 8 weeks regimen of the phase 3 trials is not among the extension's interventions.
- Enrollment is limited to participants who completed the preceding phase 3 trials (CDX0159-12 or CDX0159-13) and have at least one documented UAS7 score from Weeks 64 to 68 of those trials.
- The primary endpoint is time to disease worsening or treatment failure through Week 52, defined by UAS7 of 16 or greater, discontinuation of barzolvolimab in the retreatment group for lack of efficacy or a treatment-related adverse event, or first use of a strongly confounding prohibited medication or of barzolvolimab in the observation group. Estimated enrollment is 1370.